Drugs / HPV-16/18/31/45 L1 AS04 Formulation 5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00231413 | Mar 2005 → Mar 2006 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV-16/18/31/45 L1 AS04 Formulation 5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00231413 ↗ |
| Modality | Vaccine | “novel GSK Biologicals HPV vaccine” NCT00231413 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT00231413 ↗ |